Case study – Seqirus
Seqirus, the world’s no.2 influenza vaccine provider has recently committed investments of more than £60 million to expand its state-of the-art manufacturing site in Liverpool.
These investments are enabling Seqirus to fully manufacture seasonal and pandemic influenza vaccines in-house, from starting material right through to formulation, final packaging and delivery to markets all over the world.
Seqirus Liverpool produces the world’s only licensed adjuvant seasonal influenza vaccine, specifically designed to protect older adults.
With extensive research and production expertise and manufacturing plants in the US, UK and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.